Introduction
============

Even in the developed countries including United States of America, colorectal cancer (CRC) is the third most common cancer diagnosed in both men and women, and the second leading cause of cancer deaths.[@b1-ott-8-233] The International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) Tumor, Node, Metastasis (TNM) classification is a worldwide applied system for cancer staging. This system for assessing tumor stage which was adopted over 50 years ago provides accurate prognostic information and helps determine the treatment decisions for CRC.[@b2-ott-8-233]

In the past few years, the TNM staging system for CRC has been changed several times. One of the most radical changes is regarding tumor deposits. Tumor deposits are defined as focal aggregates of cancer nodules located in the pericolic region or in perirectal fat. These nodules are discontinuous with the primary tumor and are not associated with lymph nodes. Whether the tumor deposits should be considered as lymph node involvement when staging the disease has been the hotspot of discussion for many years which resulted in changes in classification of the disease in subsequent editions of the TNM staging system. Tumor deposits were first introduced in the fifth edition (TNM5) in 1997,[@b3-ott-8-233] in which tumor deposits greater than 3 mm in diameter were considered as lymph node metastases. In the subsequent edition (TNM6),[@b4-ott-8-233] the 3 mm standard was withdrawn and replaced by a definition of tumor deposits based on contour. In the current TNM classification (TNM7), the previous contour rule was abandoned and the new TNM staging system stated that only T1 and T2 lesions that were positive for tumor deposits but lacked regional lymph node metastasis will be classified as N1c.[@b5-ott-8-233] This induces a significant change in the TNM staging system: patients with T1 or T2 tumors that meet the N1c criteria are escalated from a stage I to stage IIIa. Similarly, patients with T3 and T4a tumors that meet these same criteria are escalated from a stage II to stage IIIb. Finally, patients with T4b tumors with these additional features are now classified as stage IIIc.

Whether the prognostic value of TNM7 is better than other editions and whether this change is reproducible still needs to be validated. Furthermore, the newest classification does not indicate how to classify the patients with both lymph node metastases and positive tumor deposits. It is still unknown whether, in the different stages of the disease, the prognostic impact of tumor deposits is different. Presently, several reports have demonstrated that tumor deposits in stage II and III CRC patients are a poor prognostic indicator,[@b6-ott-8-233]--[@b12-ott-8-233] but no study has focused on stage IV CRC patients.

In the present study, we first investigated the incidence and prognosis of tumor deposits in patients who underwent simultaneous R0 resection for synchronous colorectal liver metastases (SCRLM).

Materials and methods
=====================

Study population
----------------

We reviewed our prospectively collected SCRLM database between July 2003 and July 2013. The selection criteria for simultaneous resection have been reported previously:[@b13-ott-8-233] expected radical resection of primary cancer and margin-negative resection of liver metastases, no unresectable extrahepatic metastases and adequate volume of the post-operative liver. Patients who underwent previous hepatic resections, ablations of the liver metastases, died during the perioperative period, or had incomplete materials were also excluded from this study. All of the patients included in this study acquired simultaneous R0 resection for both their primary cancer and liver metastases which was confirmed by the postoperative pathology. This study was approved by the institutional review board of Zhongshan Hospital. All of the patients provided written consent.

Histologic evaluation of tumor deposits
---------------------------------------

For each patient, all slides were reviewed to evaluate the presence of tumor deposits together with other pathological factors. Existence of tumor deposits was defined as nodules located in the pericolic/perirectal adipose tissue of the bowel specimen without lymphocyte aggregates or in the mesocolic/mesorectal specimens harvested and collected as lymph nodes for evaluation of metastasis. Cancer nodules adjacent to metastatic lymph nodes presumed to be correlated with the process of lymph node metastasis were not considered as tumor deposits, and cancer nodules restricted to lymphatic or venous structures or tumor foci less than 5 mm of the foremost edge of the primary tumor were not considered as tumor deposits.[@b7-ott-8-233],[@b12-ott-8-233]

Data collection
---------------

Clinicopathological data from all patients were collected from our prospectively collected SCRLM database. The duration of perioperative chemotherapy was also recorded. The follow-up regimen included routine computed tomography scans of the chest, abdomen, and pelvis and regular colonoscopic surveillance. Disease recurrence was recorded on the basis of clinical, endoscopic or radiological findings at the time of diagnosis. The date of last follow-up, vital status, and recurrence were recorded for all patients. Overall survival (OS) was calculated from the date of diagnosis to the date of death due to CRC or last follow-up. Disease-free survival (DFS) was calculated from the date of surgery until the date of documented disease recurrence.

Statistical analysis
--------------------

Summary statistics were obtained using established methods and are presented as percentages or mean values with standard deviations. Categorical data are summarized as percentages and were analyzed using chi-squared analysis or Fisher's exact test. OS and DFS were analyzed using Kaplan--Meier analysis; survival curves were compared using the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards model. The prognostic factors with *P*\<0.10 in univariate analysis were entered into the Cox proportional hazards model using stepwise selection to identify independent predictors. All of the statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). Two-sided *P*-values were calculated, and *P*\<0.05 was considered significant.

Results
=======

Clinicopathological characteristics of the SCRLM patients
---------------------------------------------------------

From July 2003 to July 2013, we identified 146 patients who underwent simultaneous R0 resection of SCRLM. Detailed clinicopathological data of the 146 patients is shown in [Table 1](#t1-ott-8-233){ref-type="table"}. The majority of patients were male (56.8%) and younger than 60.0 years old (65.8%). Most patients presented with primary colon tumor (69.2%). The average number of metastases was 1.88±1.18 (1.0--7.0). The average size of the largest metastasis was 3.80±2.29 cm (0.5--15 cm). Positive tumor deposits were detected in 41.8% (61/146) of these patients. Various clinicopathologic characteristics were assessed and compared according to tumor deposits status. We found that lymph node metastasis and the nerve invasion of the primary tumors were significantly correlation with the presence of tumor deposits (*P*=0.002, *P*=0.041; respectively) ([Table 1](#t1-ott-8-233){ref-type="table"}).

Operative details and perioperative chemotherapy
------------------------------------------------

For the primary tumor operations, 38.4% (56/146) of patients underwent right hemicolectomy, 34.5% (48/146) of patients underwent left hemicolectomy, 28.8% (42/146) of patients underwent proctectomy. For the liver operations, 77.4% (113/146) underwent wedge resection, 17.1% (25/146) underwent hemihepatectomy, 1.4% (2/139) underwent extended hepatectomy, 4.1% (6/146) underwent an unknown extent of hepatic resection. As for complications, a total of 30.1% (44/146) of patients had 57 complications as follows: ascites (11), subphrenic fluid (8), pleural effusion (7), wound infection and fat liquefaction (5), small bowel obstruction (5), pneumonia and atelectasis (5), intra-abdominal infection (3), hemorrhage/hematoma (3), transient hepatic dysfunction (2), bile leakage (2), intestinal leakage (2), and others (4). All of the complications were successfully treated medically or by percutaneous drainage. Of the patients analyzed, 23.3% (34/146) of patients received preoperative chemotherapy, and all patients received adjuvant chemotherapy. The routinely used chemotherapy regiments were FOLFOX (oxaliplatin, folinic acid and fluorouracil); FOLFIRI (irinotecan, folinic acid and fluorouracil); and XELOX (capecitabine and oxaliplatin).

OS analysis
-----------

Follow-up information was obtained for the 146 patients through July 2013. The 5 year OS rate was 47.0%. The median follow-up period was 36.1 months. At the last follow-up, 29.5% (43/146) of patients had died and 51.4% (75/146) of patients experienced tumor recurrence. Of those patients 34.9% (51/146) had recurrence in the liver only, 6.8% (10/146) had recurrence in the lung only, and 9.6% (14/146) had recurrence in other sites.

To investigate the prognostic value of positive tumor deposits in the SCRLM patients, we compared OS according to the status of tumor deposits with Kaplan-- Meier survival analysis. This analysis revealed that the OS of the CRC patients who were positive for tumor deposits was significantly poorer than those patients who were negative for tumor deposits (*P*=0.039, [Figure 1A](#f1-ott-8-233){ref-type="fig"}).

In order to estimate the clinical significance of various prognostic factors that might influence survival in the study population, univariate analyses were performed for OS in the 146 patients with SCRLM using the Cox proportional hazards model. The following factors were significantly associated with poorer OS: positive lymph nodes, vascular invasion, nerve invasion, tumor deposits around the primary tumor, and the number of liver metastases (≥4). The prognostic factors with *P*\<0.10 in univariate analysis were then entered into the Cox proportional hazards model using stepwise selection to identify independent predictors. We found that positive lymph nodes (*P*=0.001), vascular invasion *(P*=0.001), and the number of liver metastases (*P*=0.004) were significantly associated with poorer prognosis. The details of the univariate and multivariate analyses are shown in [Table 2](#t2-ott-8-233){ref-type="table"}.

DFS analysis
------------

The 5 year DFS of the 146 CRLMs patients was 36.0%. We also compared DFS according to the presence of tumor deposits with a Kaplan--Meier survival analysis. This analysis revealed that the DFS of SCRLM patients with tumor deposits was significantly poorer than those patients negative for deposits (*P*=0.001; [Figure 1B](#f1-ott-8-233){ref-type="fig"}).

In univariate analyses, the number of liver metastases (≥4), extrahepatic metastases resection, and the presence of tumor deposits were significantly associated with shorter DFS. The prognostic factors with *P*\<0.10 in the univariate analysis were entered into the Cox proportional hazards model using stepwise selection to identify independent predictors. We found that the number of liver metastases (≥4) and the existence of tumor deposits were significantly associated with shorter DFS (*P*=0.007, *P*=0.002; respectively). The details of the univariate and multivariate analyses are shown in [Table 3](#t3-ott-8-233){ref-type="table"}.

Subgroup survival analysis according to the status of lymph node metastasis and tumor deposits
----------------------------------------------------------------------------------------------

In our study, of the 57 patients with negative lymph nodes, the OS and DFS of patients positive for tumor deposits were significantly shorter than those negative for tumor deposits, as analyzed with the Kaplan--Meier method (*P*=0.002 and *P*=0.031, respectively) ([Figure 2A and B](#f2-ott-8-233){ref-type="fig"}). When analyzing the 89 patients with positive lymph nodes using the same method, the OS was not significantly different (*P*=0.965) ([Figure 3A](#f3-ott-8-233){ref-type="fig"}); however, the DFS of patients positive for tumor deposits was significantly shorter than those negative for tumor deposits (*P*=0.034) ([Figure 3B](#f3-ott-8-233){ref-type="fig"}).

Discussion
==========

Presently, the latest seventh TNM staging system for CRC has caused great controversy. Some studies suggest that the seventh TNM edition does not provide greater accuracy in predicting the prognosis of CRC patients.[@b14-ott-8-233]--[@b16-ott-8-233] However, other studies indicated that the seventh TNM edition has better prognostic validity than the sixth TNM edition.[@b17-ott-8-233]--[@b19-ott-8-233] Tumor deposit is one of the important influencing factors among the different editions. How to correctly define and differentiate positive tumor deposits and lymph node metastases has confused researchers and clinicians. Some studies have demonstrated that classifying the positive tumor deposits as a type of N factor irrespective of contours can simplify the tumor staging system by enhancing diagnostic objectivity which improves prognostic accuracy.[@b10-ott-8-233],[@b12-ott-8-233],[@b20-ott-8-233]

The incidence of tumor deposits in the stage II and III CRC patients varies from 4.5% to 46.9% determined in part by the definitions and the methods of examination.[@b15-ott-8-233],[@b21-ott-8-233],[@b22-ott-8-233] It is clear that tumor deposits can present in early tumor stages. Ratto et al[@b22-ott-8-233] found that tumor deposits were present in 18.8% of TNM stage I tumors and 46.9% of TNM stage II tumors. The incidence of patients with tumor deposits increased with higher tumor stage.[@b11-ott-8-233] In our study, tumor deposits were detected in 41.8% of the SCRLM patients who underwent simultaneous R0 resection. Another study about CRC lung metastasis detected that 54.1% of patients were positive for tumor deposits.[@b23-ott-8-233] In our study, we found that the presence of tumor deposits was significantly correlated with primary lymph metastasis and nerve invasion. These results demonstrate that tumor deposits might be an invasive focus of aggressive tumor cells which originated from lymphatic channels and nerve sheath infiltrations.[@b22-ott-8-233] We also observed a statistically significant difference in the tumor deposit subgroup's survival rate according to the status of lymph nodes. These results suggest that tumor deposits should be considered independently from lymph node metastasis because of a possible difference in the impact on survival between these two modes of discontinuous spread.[@b24-ott-8-233]

Additionally, the seventh edition of TNM staging may have weakened the prognostic value of tumor deposits. Belt et al[@b11-ott-8-233] suggested that all negative lymph node stage II patients with tumor deposits, regardless of their size and shape, should be classified as stage III and that adjuvant chemotherapy should be considered for these patients because of their high risk of disease recurrence. Ueno H et al[@b8-ott-8-233] reported that the 5 year DFS was 85.0% in 695 pT3/T4 patients with CRC without tumor deposits and 59.5% in those with tumor deposits (*P*\<0.001). Multivariate analyses showed that tumor deposits affected DFS independent of T and N stages. Tong et al[@b6-ott-8-233] have suggested that patients who are categorized as T3N2bM0TD (+) and T4N2bM0TD (−/+) may be reclassified as stage IV due to their similar poor prognosis; moreover, these authors did not consider the number of tumor deposits to be a prognostically significant parameter. In our study, OS and DFS of the patients with positive tumor deposits were significantly shorter than those negative for tumor deposits. And of the patients with positive lymph nodes, the DFS of the patients positive for tumor deposits was significantly shorter than those negative for tumor deposits. Of the patients with negative lymph nodes, the OS and DFS of the patients positive for tumor deposits were significantly shorter than those who were negative. With multivariate analysis, we found that the presence of tumor deposit was significantly associated with shorter DFS independent of lymph node status. We are in agreement with another study about the CRC lung metastasis patients who underwent resection.[@b23-ott-8-233] These results together suggest that tumor deposits should be treated differently from lymph node metastasis because of a possible difference in impact on survival.

In conclusion, the presence of tumor deposits was an independent adverse prognostic factor for SCRLM patients who underwent simultaneous R0 resection. Our study was a single institution retrospective study and the number of patients was small. More research needs to be done on how to define and judge the tumor deposits to decrease the inter-observer variation.
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![Analyses of overall survival and disease-free survival according to the status of tumor deposits in synchronous colorectal liver metastases (SCRLM) patients.\
**Notes:** (**A**) Kaplan--Meier analyses of overall survival according to status of tumor deposits in SCRLM patients (n=146; *P*=0.039). (**B**) Kaplan--Meier analyses of disease-free survival according to status of tumor deposits in SCRLM patients (n=146; *P*=0.001).](ott-8-233Fig1){#f1-ott-8-233}

![Analyses of overall survival and disease-free survival according to the status of tumor deposits in synchronous colorectal liver metastases (SCRLM) patients with negative lymph node.\
**Notes:** (**A**) Kaplan--Meier analyses of overall survival according to status of tumor deposits in SCRLM patients with negative lymph node (n=57; *P*=0.002). (**B**) Kaplan--Meier analyses of disease-free survival according to status of tumor deposits in SCRLM patients with negative lymph node (n=57; *P*=0.031).](ott-8-233Fig2){#f2-ott-8-233}

![Analyses of overall survival and disease-free survival according to the status of tumor deposits in synchronous colorectal liver metastases (SCRLM) patients with positive lymph node.\
**Notes:** (**A**) Kaplan--Meier analyses of overall survival according to status of tumor deposits in SCRLM patients with positive lymph node (n=89; *P*=0.965). (**B**) Kaplan--Meier analyses of disease-free survival according to status of tumor deposits in SCRLM patients with positive lymph node (n=89; *P*=0.034).](ott-8-233Fig3){#f3-ott-8-233}

###### 

The correlation between the clinicopathological factors and the status of tumor deposits in patients who underwent simultaneous resection for synchronous colorectal liver metastases

  Variables                  Patients   Tumor deposits   *P*-value        
  -------------------------- ---------- ---------------- ----------- ---- --
  Age (years)                           0.596                             
   ≤60                       96         65.8             42          54   
   \>60                      50         34.2             19          31   
  Sex                                   0.913                             
   Male                      83         56.8             35          48   
   Female                    63         43.2             26          37   
  Tumor location                        0.424                             
   Colon                     101        69.2             40          61   
   Rectum                    45         30.8             21          24   
  Histological type                     0.304                             
   Adenocarcinoma            124        84.9             54          70   
   Mucinous adenocarcinoma   22         15.1             7           15   
  Tumor differentiation                 0.227                             
   Well, moderate            78         53.4             29          49   
   Poor and others           68         46.6             32          36   
  Primary tumor (T) stage               1.000                             
   T1, T2                    6          4.1              2           4    
   T3, T4                    140        95.9             59          81   
  Primary nodal (N) stage               0.002                             
   Absent                    57         39.0             15          42   
   Present                   89         61.0             46          43   
  Vascular invasion                     0.113                             
   Absent                    121        82.9             47          74   
   Present                   25         17.1             14          11   
  Nerve invasion                        0.041                             
   Absent                    129        88.4             50          79   
   Present                   17         11.6             11          6    
  No of metastases                      0.130                             
   ≤3                        129        88.4             51          78   
   ≥4                        17         11.6             10          7    
  Largest metastasis                    0.673                             
   \<5 cm                    105        71.9             45          60   
   ≥5 cm                     41         28.1             16          25   
  Carcinoembryonic antigen              0.952                             
   ≤5 ng/mL                  46         31.5             19          27   
   \>5 ng/mL                 98         68.5             41          57   

###### 

Univariate and multivariate analyses of associations between clinicopathological factors and overall survival in patients who underwent simultaneous resection for synchronous colorectal liver metastases

  Prognostic factor                                             Univariate analysis   Multivariate analysis                                  
  ------------------------------------------------------------- --------------------- ----------------------- ------- ------- -------------- ---------
  Age (\>60:≤60)                                                0.623                 0.320--1.214            0.165                          
  Sex (female:male)                                             1.620                 0.890--2.949            0.115                          
  Primary tumor site (rectum:colon)                             1.314                 0.706--2.443            0.389                          
  Histological type (mucinous adenocarcinoma: adenocarcinoma)   0.795                 0.313--2.023            0.631                          
  Tumor differentiation (well, moderate: poor and others)       1.564                 0.850--2.880            0.151                          
  Primary tumor (T) stage (T3, T4:T1, T2)                       2.585                 0.355--18.803           0.348                          
  Primary nodal (N) stage (N1, N2:N0)                           3.304                 1.530--7.132            0.002   4.200   1.912--9.224   \<0.001
  Vascular invasion (positive:negative)                         2.616                 1.308--5.230            0.007   3.561   1.688--7.514   0.001
  Nerve invasion (positive:negative)                            2.569                 1.068--6.177            0.035   1.622   0.651--4.042   0.299
  No of liver metastases (≥4: ≤3)                               1.485                 0.984--5.643            0.022   3.408   1.478--7.859   0.004
  Size of liver metastases (≥5 cm:\<5 cm)                       2.589                 1.145--5.854            0.237                          
  Extrahepatic metastases resection (yes:no)                    2.198                 0.677--7.134            0.190                          
  CEA (.5 ng/mL:\>5 ng/mL)                                      1.824                 0.896--3.715            0.098   1.647   0.805--3.368   0.172
  Chemotherapy (postoperative:perioperative)                    1.077                 0.561--2.069            0.824                          
  Tumor deposits (positive:negative)                            1.859                 1.019--3.389            0.043   1.541   0.820--2.895   0.179

**Abbreviations:** HR, hazard ratio; CI, confidence interval.

###### 

Univariate and multivariate analyses of associations between clinicopathological factors and disease-free survival in patients who underwent simultaneous resection for synchronous colorectal liver metastases

  Prognostic factor                                             Univariate analysis   Multivariate analysis                                  
  ------------------------------------------------------------- --------------------- ----------------------- ------- ------- -------------- -------
  Age (\>60:≤60)                                                0.671                 0.408--1.104            0.116                          
  Sex (female:male)                                             1.529                 0.971--2.409            0.067   1.541   0.976--2.432   0.063
  Primary tumor site (rectum:colon)                             1.313                 0.819--2.104            0.258                          
  Histological type (mucinous adenocarcinoma: adenocarcinoma)   0.620                 0.298--1.292            0.202                          
  Tumor differentiation (well, moderate: poor and others)       1.423                 0.898--2.255            0.133                          
  Primary tumor (T) stage (T3, T4:T1, T2)                       1.539                 0.484--4.893            0.465                          
  Primary nodal (N) stage (N1, N2:N0)                           1.611                 0.991--2.620            0.054   1.404   0.827--2.384   0.209
  Vascular invasion (positive:negative)                         1.482                 0.828--2.652            0.185                          
  Nerve invasion (positive:negative)                            1.453                 0.722--2.926            0.295                          
  No of LMs (≥4:≤3)                                             2.333                 1.251--4.351            0.008   2.380   1.268--4.469   0.007
  Size of LM (≥5 cm:\<5 cm)                                     1.420                 0.872--2.312            0.159                          
  Extrahepatic metastases resection (yes:no)                    2.670                 1.068--6.675            0.036   1.716   0.661--4.454   0.267
  CEA (\>5 ng/mL:\>5 ng/mL)                                     1.429                 0.868--2.352            0.160                          
  Chemotherapy (postoperative:perioperative)                    1.108                 0.663--1.852            0.696                          
  Tumor deposits (positive:negative)                            2.149                 1.360--3.396            0.001   2.080   1.316--3.290   0.002

**Abbreviations:** HR, hazard ratio; CI, confidence interval.
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